1. Lønnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014;7:251–9.
2. Novartis Pharmaceuticals Corporation. Advisory Committee briefing materials: secukinumab (AIN457). 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM419023.pdf . Accessed 17 Dec 2014.
3. Novartis International AG. First in the world regulatory approval of Novartis’ Cosentyx™ in Japan for both psoriasis and psoriatic arthritis [media release]. 26 Dec 2014. http://www.novartis.com/newsroom/media-releases/en/2014/1883568.shtml .
4. European Commission. Commission implementing decision for Cosentyx™ (secukinumab). 15 Jan 2015. http://ec.europa.eu/health/documents/community…/dec_130444_en.pdf . Accessed 29 Jan 2015.
5. US Food and Drug Administration. FDA approves new psoriasis drug Cosentyx [media release]. 21 Jan 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htm .